REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Investigational Peptide CS060380 Shows Promise in Combating MASH and Obesity
Back to Research Library

Investigational Peptide CS060380 Shows Promise in Combating MASH and Obesity

May 25, 2026
Share
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article is an AI-assisted summary of a recently published news item or clinical trial listing. It is intended to provide a quick, accessible overview for the peptide research community. For full accuracy, always refer to the original source linked below.

Investigational Peptide CS060380 Shows Promise in Combating MASH and Obesity

A new clinical trial aims to test the efficacy and safety of a novel investigational peptide, CS060380, when used alongside semaglutide for treating patients with metabolic dysfunction-associated steatohepatitis (MASH) and obesity. This Phase II study is an exciting development in the world of peptide therapy as it explores potential new avenues to address serious health conditions that are becoming increasingly common.

Background

Metabolic dysfunction-associated steatohepatitis, or MASH, is a condition characterized by fat accumulation in the liver, leading to inflammation and damage. It’s often associated with obesity, type 2 diabetes, and metabolic syndrome. Currently available treatments for MASH are limited and primarily focus on addressing underlying risk factors such as weight management and blood sugar control.

Semaglutide has been shown to be effective in managing obesity and improving glycemic control, but its impact on liver health specifically is still under investigation. This new study seeks to expand the understanding of semaglutide’s potential benefits when combined with CS060380—a peptide being developed by Cascade Pharmaceuticals, Inc.

Key Details

The study, titled "A Study of CS060380 Tablets in Patients With MASH and Obesity," is recruiting participants across multiple sites. Researchers will monitor the effects of a combination therapy involving semaglutide and CS060380 compared to those who receive placebo treatments.

This trial is crucial as it targets two major public health concerns: obesity and liver disease. The research aims to determine if the combined use of these peptides can improve outcomes for patients with MASH, offering hope to millions worldwide who suffer from this debilitating condition.

The study duration spans up to 54 weeks, providing ample time to assess long-term benefits and safety profiles associated with the new investigational drug CS060380. Participants will be closely monitored throughout the trial period to gather comprehensive data on the effectiveness of this novel treatment approach.

Key Takeaways

  • Novel Combination Therapy: The study explores the potential synergy between semaglutide and CS060380 for treating MASH.
  • Patient Recruitment: Researchers are actively recruiting adults who suffer from both obesity and metabolic dysfunction-associated steatohepatitis.
  • Long-term Monitoring: Participants will be followed for up to 54 weeks, ensuring detailed insights into the safety and efficacy of the treatment over time.
  • Potential for Breakthroughs: This research could pave the way for new therapeutic options in managing liver health issues linked with obesity.

What This Means

For the peptide community, this study represents a significant step forward in exploring innovative treatments for complex metabolic disorders. The combination therapy approach offers promising possibilities for improving patient outcomes and quality of life. If successful, CS060380 could become an important addition to the toolkit of medical professionals dealing with MASH and obesity.

---

Source: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07466017) — Published 2026-05-20

This article is for informational purposes only and does not constitute medical advice.

Editor's Note

This analysis was generated using AI tools and reviewed by the Peptide Contacts editorial team. While we strive for accuracy, AI-generated content may contain errors or omissions. We encourage readers to review the original source for complete details, methodology, and data.

Peptide Contacts provides curated research summaries for informational purposes only. This content does not constitute medical advice. Always consult a qualified healthcare provider before making any health decisions.

Comments

Sign in to join the discussion

This article was generated using AI and may contain inaccuracies. It is provided for informational purposes only and does not constitute medical advice. Always verify information with the original source and consult a qualified healthcare provider before making any health decisions.